In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. - Wikidata - awgldk - TriplyDB

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

http://www.wikidata.org/entity/Q34030193

about

Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells A novel knowledge representation framework for the statistical validation of quantitative imaging biomarkers Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 Photochemical internalization of tumor-targeted protein toxins.Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.Innovative Therapies against Human Glioblastoma Multiforme Tumor-targeted drug delivery with aptamers Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.Ocular neovascularisation and excessive vascular permeability.Tumour angiogenesis, vascular biology and enhanced drug delivery.In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development.Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.Endothelial cells support the growth of prostate tissue in vivo Quantitative imaging biomarker ontology (QIBO) for knowledge representation of biomedical imaging biomarkers Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.Targeted drug delivery strategies to treat lung metastasis.The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.Delivery systems for in vivo use of nucleic Acid drugs.Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.HPMA-copolymer conjugates targeted to tumor endothelium using synthetic oligopeptides.Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions).Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.In Vitro Evaluation of Vegf-Pseudomonas Exotoxin: A Conjugated on Tumor Cells.

P2860

Q24648786-70966625-BD60-42BD-A19D-EAC191C5D28F Q26825076-A1898D23-F619-4FD6-9A63-06D8B1BC4434 Q27314650-7F20D395-AD4D-4099-849A-771AB4C13201 Q27343143-BDBBC06C-D6C0-4E01-9D13-2099BCE708A8 Q33592796-4E94196D-AD0B-4945-B274-BC712F5EB2EA Q33829419-5FF8D8FC-C821-450A-A48C-DA4E83D1B9E8 Q33995228-3361124F-A396-4458-A1DA-C67B680229CB Q34068201-D24DFD83-0C8E-45CC-905E-AFB47A53CAEB Q34762148-767226DB-E6EC-47E6-AED6-0F7C6B965507 Q34768492-2FA5C2F0-5796-4D04-B51E-D3F22DC12ECE Q34771778-C425D233-C362-4486-8AE4-00049A0AC80F Q34809729-A42730DB-3E94-4D76-B275-EFBD908A47FE Q34997320-EA5DDF3E-F400-43AF-9923-90A1EB3A9906 Q35070058-ACAD1B1E-721F-4A9C-9F10-24439F6C8383 Q35374492-2AD419AE-3DB9-4E24-85D7-9725697204F4 Q35490874-69DFC82D-38DB-49B2-A0DA-72E89B00FF5E Q35580988-A3D4FCF0-1645-40FD-B60F-93170EB9D874 Q35635510-AEE95C60-DA4B-435F-9182-9E2EE6C789FB Q35873752-6E7B7ACE-99F5-4375-8D24-74ECC7A97041 Q35931998-DBCF7C42-D546-4D5F-8F07-7AAF42EB38F6 Q36384017-C2191C66-AC9E-4457-9B6B-ECAE2DBD7FCF Q36625112-875EC891-60E8-40F3-9DD7-2D20AD103197 Q36805395-0144E785-5CD9-436C-B9FA-A94421C782BE Q36993012-38143B81-8D9A-4061-972F-C068D060CBB7 Q37568306-7C3C8568-42C1-4AC3-866C-6EB212F718CA Q37575499-4707CD43-81B3-4A36-830F-59066EB4BE30 Q37577621-ACF9D6B9-AD47-4A21-95E9-0C5DC50260F1 Q37928915-2707A9C0-33FF-482A-AC92-D6E8D11155CE Q38262399-30E3C6E9-929D-421C-8D4A-4DAEF6A92428 Q38909313-C8365CEA-0D02-4679-92A4-B1FC4D148F9E Q39187821-D4374559-8CB9-47AB-9133-5E1B884EB430 Q39205186-A2DF5040-4175-433D-86A0-23B79F70513C Q39385032-569F5F4B-BF2E-4F56-AD9B-5419549D1220 Q39661859-6EC46702-999E-4192-A871-DC998BEBD340 Q39670991-2EB788D5-5D6F-4C8F-A936-E69D1E9E089D Q39782523-3C6C3C1E-0065-4EBD-AEBF-12CF330FE2FB Q40174585-8BF9DB83-D0A7-42ED-91B8-E78D724A175E Q41918293-1998215C-C075-4A41-8EAC-920F48FDB2C7 Q42413750-70515659-5E9F-4E8E-8C30-7016C12E2D1B Q47167709-2895C80E-504B-4C0B-A1A5-45B86A7227D4

P2860

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

http://www.wikidata.org/entity/Q34030193

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@ast

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@en

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@nl

type

label

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@ast

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@en

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@nl

prefLabel

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@ast

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@en

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@nl

P1433

Q34030193-EA61122A-8B26-4FEB-8465-F22784C8A298

P1476

Q34030193-560473AD-F0FD-4F19-9CF9-71A48066D4EE

P2093

Q34030193-13F459D2-AD8B-4BAE-B0C0-5C97B5D3B11E

Q34030193-1F039B1D-2FEA-45D8-B533-32135F14BCBB

Q34030193-21A147E3-7C1E-4726-9646-2FC4507EA793

Q34030193-62484792-F564-462E-ACAA-B45C8698C8FF

Q34030193-83DF48E3-006E-4F59-86FA-5EAC9F4F57A9

Q34030193-A9DD5777-D7C2-4F76-90A6-C1C8BC2874FB

Q34030193-AC31C6E9-0D96-4784-8221-FD83288D3CC3

Q34030193-C8EDE981-B5FD-4314-AD61-3F957B5F0979

Q34030193-FA46A182-B0E4-4ACF-91B4-905F99D9E32A

P2860

Q34030193-0B65D15D-938C-4D6A-9D9B-48B9C9612C68

Q34030193-0D644CDB-59D4-4AF1-AB0D-F698BA6A46FF

Q34030193-1FBD1080-2993-45E1-BD53-7F9B8388FFC4

Q34030193-291EF8DC-1730-42FE-9FA9-D2B78EF7709E

Q34030193-2D72898E-B488-464E-B966-0B3E35F9094B

Q34030193-3444E89B-045D-4112-9816-15A15530C59A

Q34030193-395988E0-D3F3-4E9C-983F-8B8CA91DBBE1

Q34030193-4033FA8B-7D83-4047-991C-0F58A47A297E

Q34030193-50E6074E-B2C8-45D4-915E-8AB65D0BD443

Q34030193-5EDC8A87-4448-4F1E-874E-9821389A4696

P304

Q34030193-BE7D2C79-330C-4B24-B084-4498923D5D1C

P31

Q34030193-FFDE0567-8DE5-445F-B21B-7D362B03E45C

P356

Q34030193-8947AB8B-5422-42A3-BD52-63E92BD3B695

P407

Q34030193-8715C1DD-DC4D-49B1-A286-E6AA83E91A07

P433

Q34030193-14253C90-5A5D-4470-BEE3-987359F84180

P478

Q34030193-D082932E-25DD-4253-AE51-4EA0CEFF36F7

P577

Q34030193-3B128ABA-D8F7-43CE-92C2-7F063CB71AAB

P5875

Q34030193-DADCE5A9-93B3-4CB2-8B54-989397D22A71

P698

Q34030193-D18BAE85-F4B2-4833-B29B-0C05DDA81A03

P932

Q34030193-556E6F60-C554-44E1-B50D-0B3E03E8DC39

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

In vitro and in vivo studies o ...... eovasculature of solid tumors.

@en

P2093

Hangqing Jin

http://www.w3.org/2001/XMLSchema#string

Johannes Waltenberger

http://www.w3.org/2001/XMLSchema#string

John W Marks

http://www.w3.org/2001/XMLSchema#string

Lawrence Cheung

http://www.w3.org/2001/XMLSchema#string

Liesbeth M Veenendaal

http://www.w3.org/2001/XMLSchema#string

Michael G Rosenblum

http://www.w3.org/2001/XMLSchema#string

Nora Navone

http://www.w3.org/2001/XMLSchema#string

Philip Thorpe

http://www.w3.org/2001/XMLSchema#string

Sophia Ran

http://www.w3.org/2001/XMLSchema#string

P2860

Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization

Genes expressed in human tumor endothelium

Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

Molecular, biological, and preliminary structural analysis of recombinant bryodin 1, a ribosome-inactivating protein from the plant Bryonia dioica

Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis

Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor

Vascular endothelial growth factor is a secreted angiogenic mitogen

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

P304

7866-7871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.122157899

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11313124

http://www.w3.org/2001/XMLSchema#string

P698

12060733

http://www.w3.org/2001/XMLSchema#string

P932

122986

http://www.w3.org/2001/XMLSchema#string